Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 11/20 | 0.49 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12711105 | 0.96 | DUT (0.47) | DUTKAT6AACACBPTGS1PTGS2 | |
| SCHEMBL12630553 | 0.84 | DUT (0.67) | DUT | |
| SCHEMBL12711107 | 0.83 | DUT (0.50) | DUTKAT6AACACBPTGS1PTGS2 | |
| SCHEMBL12711116 | 0.83 | DUT (0.49) | DUTACACB | |
| SCHEMBL12630551 | 0.79 | DUT (0.66) | DUT | |
| SCHEMBL21315518 | 0.79 | DUT (0.66) | DUT | |
| SCHEMBL12711111 | 0.78 | DUT (0.47) | DUTACACB | |
| SCHEMBL12711136 | 0.74 | TP53 (0.39) | DUT | |
| SCHEMBL18713484 | 0.74 | DUT (0.46) | DUTKAT6AACACBPTGS1PTGS2 | |
| SCHEMBL13606345 | 0.74 | DUT (0.62) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530490-B2 | Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20110082163-A1 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082163-A1 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY | SNRPB2, SNRPA1, DUT | DUT 3/4885KAT6A 4114/4885ACACB 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.